{
    "patient": {
        "Name": "Tyler Mason",
        "DateOfBirth": "1982-05-02",
        "Sex": "Male",
        "Diagnosis": "Merkel cell carcinoma",
        "BodyPart": "Skin",
        "Physician": "Dr. Cheryl Santos",
        "TreatingInstitution": "Contreras LLC"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Skin",
            "CollectedDate": "2023-09-23",
            "ReceivedDate": "2023-09-23",
            "TumorPercentage": "33%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-09-24",
            "ReceivedDate": "2023-09-29"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.2039C>T",
                "GeneMutation": "p.V592A Nonsense-LOF",
                "VariantAlleleFraction": "3.72%"
            },
            {
                "Gene": "HDAC1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Y303H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "12.51%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.389G>C",
                "GeneMutation": "p.L182* Nonsense-LOF",
                "VariantAlleleFraction": "29.33%"
            },
            {
                "Gene": "FGFR4",
                "DNA Alteration": "c.1162G>A",
                "GeneMutation": "p.G388R Frameshift-LOF",
                "VariantAlleleFraction": "2.8%"
            },
            {
                "Gene": "PTPN11",
                "DNA Alteration": "c.1508G>C",
                "GeneMutation": "p.R130G Frameshift-GOF",
                "VariantAlleleFraction": "1.35%"
            },
            {
                "Gene": "MSH2",
                "DNA Alteration": "c.1906G>C",
                "GeneMutation": "p.R130Q Frameshift-LOF",
                "VariantAlleleFraction": "10.1%"
            },
            {
                "Gene": "MTOR",
                "DNA Alteration": "c.5664C>G",
                "GeneMutation": "p.R130P Nonsense-LOF",
                "VariantAlleleFraction": "5.02%"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.121A>G",
                "GeneMutation": "p.S37F Spliceregionvariant-GOF",
                "VariantAlleleFraction": "1.29%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "MYCN",
            "PTCH1",
            "HSP90B1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "43 m/Mb",
            "Tmbpercentile": "92%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "HBA2",
                "DNA Alteration": "c.427T>C",
                "GeneMutation": "p.*143Qext*31 Nonsense-LOF",
                "VariantAlleleFraction": "4.75%"
            },
            {
                "Gene": "CHEK2",
                "DNA Alteration": "c.1283C>T",
                "GeneMutation": "p.S428F Spliceregionvariant-GOF",
                "VariantAlleleFraction": "8.73%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.380G>C",
                "GeneMutation": "p.R127P Nonsense-GOF",
                "VariantAlleleFraction": "3.1%"
            },
            {
                "Gene": "BRAF",
                "DNA Alteration": "c.1406G>T",
                "GeneMutation": "p.L597R Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "9.51%"
            },
            {
                "Gene": "HDAC1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Y303H Frameshift-LOF",
                "VariantAlleleFraction": "8.59%"
            },
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.545T>G",
                "GeneMutation": "p.R130L Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.81%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.11%"
            },
            {
                "Gene": "APC",
                "DNA Alteration": "c.3920T>A",
                "GeneMutation": "p.I1307K Spliceregionvariant-GOF",
                "VariantAlleleFraction": "4.81%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Frameshift-LOF",
                "VariantAlleleFraction": "7.08%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Nonsense-GOF",
                "VariantAlleleFraction": "1.93%"
            },
            {
                "Gene": "HBA2",
                "DNA Alteration": "c.427T>C",
                "GeneMutation": "p.*143Qext*31 Spliceregionvariant-GOF",
                "VariantAlleleFraction": "3.18%"
            },
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Stopgain-LOF",
                "VariantAlleleFraction": "8.88%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "PHF6",
        "SDHB"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.2039C>T",
                "GeneMutation": "p.V592A Nonsense-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "3.72%"
            },
            {
                "Gene": "HDAC1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Y303H Missensevariant(exon2)-GOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "12.51%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "PTEN",
                "DNA Alteration": "c.389G>C",
                "GeneMutation": "p.L182* Nonsense-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "29.33%"
            },
            {
                "Gene": "FGFR4",
                "DNA Alteration": "c.1162G>A",
                "GeneMutation": "p.G388R Frameshift-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "2.8%"
            },
            {
                "Gene": "PTPN11",
                "DNA Alteration": "c.1508G>C",
                "GeneMutation": "p.R130G Frameshift-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "1.35%"
            },
            {
                "Gene": "MSH2",
                "DNA Alteration": "c.1906G>C",
                "GeneMutation": "p.R130Q Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "10.1%"
            },
            {
                "Gene": "MTOR",
                "DNA Alteration": "c.5664C>G",
                "GeneMutation": "p.R130P Nonsense-LOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "5.02%"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.121A>G",
                "GeneMutation": "p.S37F Spliceregionvariant-GOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "1.29%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-09-22"
    },
    "other": {
        "ReportId": "3351",
        "ReportDate": "2023-09-30",
        "SignedBy": "Cheryl Santos",
        "Supervisor": "Dr. Jose Lopez"
    }
}